EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort

Eve Denton iD, Mark Hew iD, Matthew J Peters iD, John W Upham iD, Lakmini Bulathsinhala iD, Trung N Tran iD, Neil Martin iD, Celine Bergeron iD, Mona Al-Ahmad iD, Alan Altraja iD, Désirée Larenas-Linnemann iD, Ruth Murray iD und 48 weitere

Allergy · 2024-10 · 79 (10) · 2700-2716

DOI: 10.1111/all.16178 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Allergy, online erschienen am 22.06.2024. Verfasst von Eve Denton und 59 weiteren Autor:innen. Beteiligte Einrichtung: Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: Asthma, Registries, Biological Products, Anti-Asthmatic Agents. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: AstraZeneca, Optimum Patient Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Biologic asthma therapies reduce exacerbations and long‐term oral corticosteroids (LTOCS) use in randomized controlled trials (RCTs); however, there are limited data on outcomes among patients ineligible for RCTs. Hence, we investigated responsiveness to biologics in a real‐world population of adults with severe asthma.

Methods

Adults in the International Severe Asthma Registry (ISAR) with ≥24 weeks of follow‐up were grouped into those who did, or did not, initiate biologics (anti‐IgE, anti‐IL5/IL5R, anti‐IL4/13). Treatment responses were examined across four domains: forced expiratory volume in 1 second (FEV 1 ) increase by ≥100 mL, improved asthma control, annualized exacerbation rate (AER) reduction ≥50%, and any LTOCS dose reduction. Super‐response criteria were: FEV 1 increase by ≥500 mL, new well‐controlled asthma, no exacerbations, and LTOCS cessation or tapering to ≤5 mg/day.

Results

5.3% of ISAR patients met basic RCT inclusion criteria; 2116/8451 started biologics. Biologic initiators had worse baseline impairment than non‐initiators, despite having similar biomarker levels. Half or more of initiators had treatment responses: 59% AER reduction, 54% FEV 1 increase, 49% improved control, 49% reduced LTOCS, of which 32%, 19%, 30%, and 39%, respectively, were super‐responses. Responses/super‐responses were more frequent in biologic initiators than in non‐initiators; nevertheless, ~40–50% of initiators did not meet response criteria.

Conclusions

Most patients with severe asthma are ineligible for RCTs of biologic therapies. Biologics are initiated in patients who have worse baseline impairments than non‐initiators despite similar biomarker levels. Although biologic initiators exhibited clinical responses and super‐responses in all outcome domains, 40–50% did not meet the response criteria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AsthmaRegistriesBiological ProductsAnti-Asthmatic AgentsSeverity of Illness IndexHumansMaleFemaleMiddle AgedTreatment OutcomeAdultCohort StudiesAged

Stichwörter der Autor:innen

International Severe Asthma Registry (ISAR)asthmabiologicsclinical responsemonoclonal antibodiessuper‐responders

Substanzen

Biological ProductsAnti-Asthmatic Agents

Autor:innen und Institutionen

  • Allergy, Asthma & Clinical Immunology, Alfred Health, Melbourne, Victoria, Australia.
  • Department of Medicine, Central Clinical School, Monash University, Melbourne, Victoria, Australia.
  • Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
  • Department of Thoracic Medicine, Concord Hospital, Sydney, New South Wales, Australia.
  • Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, New South Wales, Australia.
  • Frazer Institute & PA-Southside Clinical Unit, The University of Queensland, Brisbane, Queensland, Australia.

ORCID-Profile: Eve Denton, Mark Hew, Matthew J Peters, John W Upham, Lakmini Bulathsinhala, Trung N Tran, Neil Martin, Celine Bergeron, Mona Al-Ahmad, Alan Altraja, Désirée Larenas-Linnemann, Ruth Murray, Carlos Andrés Celis-Preciado, Riyad Al-Lehebi, Manon Belhassen, Mohit Bhutani, Sinthia Z Bosnic-Anticevich, Arnaud Bourdin, Guy G Brusselle, John Busby, Giorgio Walter Canonica, Enrico Heffler, Jérémy Charriot, George C Christoff, Li Ping Chung, Borja G Cosio, Andréanne Côté, Richard W Costello, Breda Cushen, James Fingleton, João A Fonseca, Peter G Gibson, Liam G Heaney, Erick Wan-Chun Huang, Takashi Iwanaga, David J Jackson, Mariko Siyue Koh, Lauri Lehtimäki, Jorge Máspero, Bassam Mahboub, Andrew N Menzies-Gow, Patrick D Mitchell, Nikolaos G Papadopoulos, Andriana I Papaioannou, Luis Perez-de-Llano, Diahn-Warng Perng, Paul E Pfeffer, Todor A Popov, Celeste M Porsbjerg, Chin Kook Rhee, Nicolas Roche, Mohsen Sadatsafavi, Sundeep Salvi, Johannes Martin Schmid, Chau-Chyun Sheu, Concetta Sirena, Carlos A Torres-Duque

Förderung

  • AstraZeneca
  • Optimum Patient Care

Zitieren

APA

Denton, E., Hew, M., Peters, M. J., Upham, J. W., Bulathsinhala, L., Tran, T. N., Martin, N., Bergeron, C., Al-Ahmad, M., Altraja, A., Larenas-Linnemann, D., Murray, R., Celis-Preciado, C. A., Al-Lehebi, R., Belhassen, M., Bhutani, M., Bosnic-Anticevich, S. Z., Bourdin, A., Brusselle, G. G., …, & Patel, P. H. (2024). Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort. Allergy, 79(10), 2700-2716. https://doi.org/10.1111/all.16178

Vancouver

Denton E, Hew M, Peters MJ, Upham JW, Bulathsinhala L, Tran TN, et al. Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort. Allergy. 2024;79(10):2700-2716. doi:10.1111/all.16178

BibTeX
@article{Denton2024,
  author = {Denton, Eve and Hew, Mark and Peters, Matthew J and Upham, John W and Bulathsinhala, Lakmini and Tran, Trung N and Martin, Neil and Bergeron, Celine and Al-Ahmad, Mona and Altraja, Alan and Larenas-Linnemann, Désirée and Murray, Ruth and Celis-Preciado, Carlos Andrés and Al-Lehebi, Riyad and Belhassen, Manon and Bhutani, Mohit and Bosnic-Anticevich, Sinthia Z and Bourdin, Arnaud and Brusselle, Guy G and Busby, John and Canonica, Giorgio Walter and Heffler, Enrico and Chapman, Kenneth R and Charriot, Jérémy and Christoff, George C and Chung, Li Ping and Cosio, Borja G and Côté, Andréanne and Costello, Richard W and Cushen, Breda and Fingleton, James and Fonseca, João A and Gibson, Peter G and Heaney, Liam G and Huang, Erick Wan-Chun and Iwanaga, Takashi and Jackson, David J and Koh, Mariko Siyue and Lehtimäki, Lauri and Máspero, Jorge and Mahboub, Bassam and Menzies-Gow, Andrew N and Mitchell, Patrick D and Papadopoulos, Nikolaos G and Papaioannou, Andriana I and Perez-de-Llano, Luis and Perng, Diahn-Warng and Pfeffer, Paul E and Popov, Todor A and Porsbjerg, Celeste M and Rhee, Chin Kook and Roche, Nicolas and Sadatsafavi, Mohsen and Salvi, Sundeep and Schmid, Johannes Martin and Sheu, Chau-Chyun and Sirena, Concetta and Torres-Duque, Carlos A and Salameh, Laila and Patel, Pujan H},
  title = {Real‐world biologics response and super‐response in the International Severe Asthma Registry cohort},
  journal = {Allergy},
  year = {2024},
  volume = {79},
  number = {10},
  pages = {2700--2716},
  doi = {10.1111/all.16178}
}
Kostenlos starten →